Industry Reports
Furiex Pharmaceuticals Enters into Loan Agreement for up to $15 Million Furiex Pharmaceuticals Inc.
Furiex Pharmaceuticals, Inc. announced it has entered into a loan agreement with MidCap Financial and Silicon Valley Bank to provide up to $15.0 million in capital through a secured term loan. Furiex intends to use the proceeds to support...
Industry Reports
China Shenghuo Q2 sales climb 58%
China Shenghuo, engaged in the research, development, manufacture and marketing of Sanchi-based medicinal and pharmaceutical, nutritional supplement and cosmetic products, has reported sales of $10.9m for the second quarter ended 30 June 2011, an increase of 58% compared to...
Industry Reports
Vivus reports Qnexa phase 3 study results
Vivus, a developer of therapies to address obesity, sleep apnea, diabetes and male sexual health, has reported the data of Qnexa in its Phase 3 study.Qnexa is an once-a-day, oral, controlled-release investigational drug candidate designed to decrease appetite, increase...
Industry Reports
Novartis delivers strong financial results and four major approvals
Novartis' net sales rose 27% (+19% cc) to USD 14.9 billion. Currency benefited sales by 8% as the US dollar weakened against most currencies. Recently launched products grew 46% over the previous-year quarter, contributing USD 3.8 billion to total...
Industry Reports
Echo Therapeutics Announces First Quarter 2011 Financial Results
Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced results for the period ended March...
Industry Reports
ELC Group announces doubled revenues
ELC GROUP, the pan-European pharmaceutical regulatory affairs organisation announced today a total revenue increase of 94% for the first quarter of 2011. ELC Group published their annual results in January and predicted a gain in net revenues for the...
Industry Reports
GlaxoSmithKline Pharmaceuticals Net Sales up 11.4%
GlaxoSmithKline Pharmaceuticals Limited has announced its financial results for the first quarter ended 31st March 2011. Profit after tax but before Exceptional Item grew by 16%. While the overall sales grew by 11.4%, net sales of the pharmaceuticals business...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
